Compare PNRG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | LRMR |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.4M | 280.0M |
| IPO Year | 1995 | 2014 |
| Metric | PNRG | LRMR |
|---|---|---|
| Price | $212.50 | $4.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.29 |
| AVG Volume (30 Days) | 31.6K | ★ 6.5M |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.81 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $237,796,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.31 | ★ N/A |
| Revenue Growth | ★ 79.05 | N/A |
| 52 Week Low | $126.40 | $1.61 |
| 52 Week High | $238.20 | $6.42 |
| Indicator | PNRG | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 53.74 |
| Support Level | $159.14 | $3.18 |
| Resistance Level | N/A | $5.37 |
| Average True Range (ATR) | 9.78 | 0.61 |
| MACD | 1.52 | 0.03 |
| Stochastic Oscillator | 84.87 | 57.49 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.